The impact of genomics on the future of medicine and health

Medical Journal of Australia

Volumn 201, Issue 1, 2014, Pages 17-20

  Mattick, John S ^a,b   Dziadek, Marie A ^a   Terrill, Bronwyn N ^a   Kaplan, Warren ^a,b   Spigelman, Allan D ^b,c   Bowling, Frank G ^a   Dinger, Marcel E ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOINFORMATICS; BONE MARROW TRANSPLANTATION; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; DRUG DESIGN; DRUG SENSITIVITY; ELECTRONIC MEDICAL RECORD; EXOME; FUNDING; GENE SEQUENCE; GENE THERAPY; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH IMPACT ASSESSMENT; HEALTH STATUS; HUMAN; HUMAN GENOME; MEDICAL RECORD; MOLECULARLY TARGETED THERAPY; NEOPLASM; PHARMACOGENOMICS; PRESCRIPTION; PROGRAM IMPACT; QUALITY OF LIFE;

AUSTRALIA; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; FORECASTING; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENETIC PRIVACY; GENOMICS; HETEROZYGOTE DETECTION; HUMANS; INDIVIDUALIZED MEDICINE; INTERNATIONAL COOPERATION; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; QUALITY OF LIFE;

EID: 84904515043     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.10920     Document Type: Article

References (23)

1. Lander ES, Linton LM, Birren B et al; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
2. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
3. National Human Genome Research Institute. DNA sequencing costs: data from the NHGRI Genome Sequencing Program (GSP). NHGRI, 2013. http://www.genome.gov/sequencingcosts (accessed Feb 2014).
4. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82-93.
5. National Cancer Institute. Targeted cancer therapies. NIH, 2012. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted (accessed Feb 2014).
6. Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 2011; 305: 1577-1584.
7. Jones SJ, Laskin J, Li YY, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol 2010; 11: R82.
8. Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012; 119: 1596-1603.
9. Lo D, Chiu RW. Plasma nucleic acid analysis by massively parallel sequencing: pathological insights and diagnostic implications. J Pathol 2011; 225: 318-323.
10. Sheffield LJ, Phillimore HE. Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev 2009; 30: 55-65.
11. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012; 30: 1117-1124.
12. Collins FS. Mining for therapeutic gold. Nat Rev Drug Discov 2011; 10: 397.
13. Royal College of Pathologists of Australia. RCPA catalogue of genetic tests and laboratories. RCPA, 2009. http://genetictesting.rcpa.edu.au (accessed Feb 2014).
14. Hahn SH. Targeted next-generation sequencing expands the spectrum of mitochondrial disorders. Genome Med 2012; 4: 22.
15. Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 2010; 362: 1181-1191.
16. Bainbridge MN, Wiszniewski W, Murdock DR, et al. Whole-genome sequencing for optimized patient management. Sci Transl Med 2011; 3: 87re3.
17. National Health and Medical Research Council. Direct-to-consumer DNA genetic testing: an information resource for consumers. Australian Government, 2012. http://www.nhmrc.gov.au/guidelines/publications/ ps0004 (accessed Jan 2014).
18. PHG Foundation. Next steps in the sequence: the implications of whole genome sequencing for health in the UK. Cambridge, UK: PHG Foundation, 2011. http://www.phgfoundation.org/file/10363 (accessed Feb 2014).
19. National Institutes of Health. NIH program explores the use of genomic sequencing in newborn healthcare. US Department of Health and Human Services, 2013. http://www.nih.gov/news/health/sep2013/nhgri-04.htm (accessed Feb 2014).
20. A Global Alliance for Genomics and Health. Creating a global alliance to enable responsible sharing of genomic and clinical data. GA4GH, 2013. http://oicr.on.ca/files/public/White_paper_2013_06_03_FINAL.pdf (accessed Feb 2014).
21. Marteau TM, French DP, Griffin SJ, et al. effects of communicating DNA-based disease risk estimates on risk-reducing behaviours (review). Cochrane Database Syst Rev 2010; (10): CD007275.
22. Department of Health. The 100K Genome Project. Genomics England: 2014. http://www.genomicsengland.co.uk (accessed Feb 2014).
23. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. Nature 2011; 470: 204-213.